Filing Flows › 8-K events › Voyager Therapeutics
Voyager Therapeutics: completion of an acquisition or disposition of assets
Form 8-K filed Nov 5, 2026 · items 2.01
Completion of an acquisition or disposition of assetsVoyager Reports Third Quarter 2026 Financial and Operating Results
What the filing says
- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - - Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter the clinic in the coming months -
Read the filing on SEC EDGAR →
What usually followsAcross 2,671 8-Ks reporting Item 2.01 (completed acquisition or disposition) in our universe, the stock's median move the next session was +0.1% (typical size ±1.6%, up 52% of the time); over the following 21 sessions, +1.2%. Every item ranked →
What this kind of filing means
Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.
Voyager Therapeutics at a glance
Voyager Therapeutics, Q3 2026: revenue $4.0M (-70% year over year), operating margin -658.2%. The chart follows the revenue to costs, profit and cash.
Voyager Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.